Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007–18
Authors:
- 1 September 2016
- journal article
- research article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 35 (9) , 1588-1594
Abstract
The Orphan Drug Act of 1983 established incentives for the development of drugs that treat rare, or orphan, diseases. We used the IMS Health MIDAS database of audited biopharmaceutical sales to measure US annual spending on orphan drugs in the period 2007–13, and we estimated spending on the drugs for the period 2014–18. We identified 356 brand-name orphan drugs that were approved by the Food and Drug Administration in the period 1983–2013. While we included orphan drugs with both orphan and other indications, we adjusted spending to include only spending for orphan indications. In 2014 dollars, expenditures on orphan drugs totaled $15 billion in 2007 and $30 billion in 2013—representing 4.8 percent and 8.9 percent of total pharmaceutical expenditures, respectively. Our future trend analysis for the period 2014–18 suggests a slowing in the growth of orphan drug expenditures. The overall impact of orphan drugs on payers’ drug budgets is relatively small, and spending on orphan drugs as a percentage of total pharmaceutical expenditures has remained fairly stable. Concerns that growth in orphan drug expenditures may lead to unsustainable drug expenditures do not appear to be justified.Keywords
This publication has 16 references indexed in Scilit:
- National Health Spending In 2013: Growth Slows, Remains In Step With The Overall EconomyHealth Affairs, 2015
- Orphan drugs expenditure in the Netherlands in the period 2006–2012Orphanet Journal of Rare Diseases, 2014
- Are payers treating orphan drugs differently?Journal of Market Access & Health Policy, 2014
- Estimating the budget impact of orphan drugs in Sweden and France 2013–2020Orphanet Journal of Rare Diseases, 2014
- Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Orphanet Journal of Rare Diseases, 2011
- Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007Applied Health Economics and Health Policy, 2010
- Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 yearsNature Reviews Drug Discovery, 2010
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy, 2010
- Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013Journal of Medical Economics, 2010
- The Economics of Orphan Drug Policy in the USPharmacoEconomics, 1995